Figure 3 from Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
Year: 2026
Type: other
Abstract: A,HER2 mutation VAF at pretreatment, on-treatment, and EOT stages in patients treated with either neratinib monotherapy or N + T. Note: Patient 21 (PR; treated with N + T) did not have an on-treatment sample and was therefore not included in this figure. B, Emergent mutations at progression in ctDNA from patients who experienced a clinical response. Circle sizes are approximately proportional to VAFs. Hollow circles indicate mutation not detectable at that time point. mCR, metabolic CR; mSD, metabolic SD; N, neratinib; PD, progressive disease; T, trastuzumab.
Authors: Komal Jhaveri, Lisa D. Eli, Sara A. Hurvitz, Adam Brufsky, Ron Bose, María de Miguel, Nisha Unni, Sonya Reid, David I. Quinn, Devalingam Mahalingam, Cristina Saura Manich, José Ángel García-Sáenz, Alejandro Martínez-Bueno, Angel Guerrero-Zotano, Olivier Trédan, Hans Wildiers, Georg F. Bischof, Judith Bebchuk, David B. Solit
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7204891723